Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks~* HbA1c greater than or equal to 7.0% and less than 10.0%~* BMI less than 35 kg/m2~Exclusion Criteria:~* Treatment with insulin within the last 12 weeks~* Treatment with any drug that could interfere with the glucose level~* Any serious medical condition~* Females who are pregnant, have intention of becoming pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.6 mg + SU (Type: EXPERIMENTAL): Liraglutide 0.6 mg + sulphonylurea
- 0.9 mg + SU (Type: EXPERIMENTAL): Liraglutide 0.9 mg + sulphonylurea
- SU Mono - 1 (Type: PLACEBO_COMPARATOR): Liraglutide placebo 0.6 mg + sulphonylurea
- SU Mono - 2 (Type: PLACEBO_COMPARATOR): Liraglutide placebo 0.9 mg + sulphonylurea

Based on this trial design, predict the completion outcome and termination type (if applicable).